Hi-Tech Pharmacal third-quarter revenues up 18% with "strong" sales from branded OTCs.
This article was originally published in The Tan Sheet
Executive Summary
HI-TECH PHARMACAL THIRD-QUARTER SALES RISE 18% to $4.7 mil. for the period ended Jan. 31. The company attributed the increase to "strong sales" by its Health Care Products division and a contribution from Rose Labs, which was acquired in November 1994. The Health Care division sells company-brand OTCs under the H-T, Sooth-It and Diabetic Tussin brands. Rose Labs manufactures private-label suppository products ("The Tan Sheet" Nov. 7, 1994, In Brief)
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.